Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (2074)	4/15/2004 4:07:20 AM
From: Icebrg	Read Replies (2) \| Respond to of 3044

Roberto Guerciolini [There appears to be a fair number of people leaving Millennium for whatever reasons. Guerciolini seems to have found himself in a situation, where some if not all of his projects were killed. It is however a trend that needs watching.] BOULDER, Colo., April 14 /PRNewswire-FirstCall/ -- Sirna Therapeutics, Inc. (Nasdaq: RNAI) announced today that Roberto Guerciolini, M.D., formerly at Millennium Pharmaceuticals, has joined Sirna as Senior Vice President of Development and Chief Medical Officer, effective immediately. In this newly created position, Dr. Guerciolini will be responsible for Sirna Therapeutics' clinical development activities and regulatory affairs. Howard W. Robin, Sirna's President and Chief Executive Officer, stated,"Dr. Guerciolini brings to Sirna tremendous experience throughout all phases of the drug development process, from the initiation of clinical programs to the filing of successful NDAs for commercialized products. We are delighted to have attracted someone of Roberto's caliber to head development and regulatory affairs as we rapidly transition to the clinic with our proprietary siRNA compounds." Sirna expects to file its first IND application in age-related macular degeneration with the U.S. Food & Drug Administration by the end of 2004. About Dr. Roberto Guerciolini In his most recent position as Senior Director of Clinical Pharmacology and Experimental Medicine at Millennium, Dr. Guerciolini was responsible for overseeing the conduct of early stage clinical trials in the areas of inflammation and metabolic diseases. He also contributed significantly towards the successful filing of an NDA for VELCADE(R), a treatment for multiple myeloma. Prior to this, he served as Director, Medical Research at Roche Global Development and Director, Clinical Pharmacodynamics/International Clinical Research at Hoffmann-La Roche, with responsibilities for phase I clinical studies in a number of therapeutic areas. He also played an important role in the filing and registration of XENICAL(R) in the U.S. and Europe for the treatment of obesity. Previously, he was Associate Director of Clinical Pharmacology/Clinical Research at Schering-Plough Corporation. Dr. Guerciolini has presented major clinical research findings at the leading health science conferences and has authored or co-authored 40 articles in peer-reviewed journals. He received his medical degree and board certification in internal medicine from the University of Perugia Medical School in Italy and completed his postdoctoral fellowship in clinical pharmacology at the Mayo Clinic. He is also certified by the American Board of Clinical Pharmacology. In addition to his medical training, Dr. Guerciolini received his Executive MBA from the Hass School of Business, University of California-Berkeley.